FDA Approves Aphexda (motixafortide) to Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
Aphexda is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade
One dosage of Aphexda plus filgrastim enabled a majority of patients to achieve the collection goal of≥ 6 million...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Filgrastim | Myeloma | Neulasta | Neupogen | Stem Cell Therapy | Stem Cells | Transplants